Serody and Basch named to leadership roles at UNC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jonathan Serody was named chief of hematology and Ethan Basch was named chief of oncology at University of North Carolina School of Medicine Department of Medicine.

Melba Ribeiro will serve both divisions as associate chief for administration.

The appointments are part of a realignment of the Division of Hematology and Oncology that will form two divisions from one.

“The division of hematology and oncology has grown substantially under the leadership of Dr. Lisa Carey,” Ron Falk, chair of the University of North Carolina School of Medicine’s Department of Medicine, said in a statement. “As Dr. Carey transitions to her new role as deputy director of clinical sciences at [UNC Lineberger Comprehensive Cancer Center], we’ve determined that having two divisions, tightly linked, will help us more efficiently manage administration for these subspecialties and position them for future growth.”

The North Carolina Cancer Hospital is the clinical home for the Lineberger Comprehensive Cancer Center.

Serody, the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology, is the associate chief of malignant hematology, bone marrow transplant and cellular therapy and the director of UNC’s Bone Marrow Transplantation & Cellular Therapy Program. He also serves as the associate director for Translational Science at the UNC Lineberger.

Basch is the Richard M. Goldberg Distinguished Professor in Medical Oncology and is focused clinically on the treatment of prostate cancer. He leads a longstanding research program focused on cancer care delivery transformation and patient-centered care, and directs the Outcomes Research Program for UNC Lineberger.

His group established that integrating patient-reported outcome symptom monitoring into routine cancer care improves patients’ quality of life, reduces emergency department visits, and lengthens overall survival. Basch developed a system for patient adverse event reporting in clinical trials, the PRO-CTCAE, that is now a standard in oncology drug development.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login